Select Page
CBMG: FDA Designations for Cell Therapy to Treat DLBCL

CBMG: FDA Designations for Cell Therapy to Treat DLBCL

The U.S. Food and Drug Administration (FDA) has granted both a Fast Track Designation and a Regenerative Medicine Advanced Therapy Designation (RMAT) to Cellular Biomedicine’s (CBMG) autologous b-specific therapy, C-CAR039, for the treatment of patients with diffuse...
Advanced NSCLC: EC Approval of Lumykras Treatment

Advanced NSCLC: EC Approval of Lumykras Treatment

The European Commission (EC) has granted a conditional marketing authorization for Amgen’s LUMYKRAS (sotorasib) to treat advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation in adults. NSCLC is the leading lung cancer diagnosis globally and includes...

We've Rebranded!

CSOFT Health Sciences is now Sesen.

Visit Sesen.com